TA50 Stock Overview A biotechnology company, develops novel circular RNA and immunotherapy medicines. More details
Rewards Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Circio Holding ASA Competitors Price History & Performance
Summary of share price highs, lows and changes for Circio Holding Historical stock prices Current Share Price NOK 0.0006 52 Week High NOK 0.90 52 Week Low NOK 0.0002 Beta 1.5 1 Month Change -98.50% 3 Month Change -98.50% 1 Year Change -99.90% 3 Year Change -99.99% 5 Year Change -100.00% Change since IPO -100.00%
Recent News & Updates
Now 98% undervalued after recent price drop Nov 02
Circio Holding ASA Presents Circvec Circular RNA in Vivo Expression Proof-Of-Concept Data At ESGCT 2024 Annual Meeting Oct 24
New major risk - Revenue and earnings growth Sep 30
New major risk - Financial position Aug 30
Circio Announces Strengthened in Vivo Data and Enhanced Circvec 2.2 Design Jun 18
New major risk - Shareholder dilution Jun 12 See more updates
Now 98% undervalued after recent price drop Nov 02
Circio Holding ASA Presents Circvec Circular RNA in Vivo Expression Proof-Of-Concept Data At ESGCT 2024 Annual Meeting Oct 24
New major risk - Revenue and earnings growth Sep 30
New major risk - Financial position Aug 30
Circio Announces Strengthened in Vivo Data and Enhanced Circvec 2.2 Design Jun 18
New major risk - Shareholder dilution Jun 12 Circio Holding ASA has filed a Follow-on Equity Offering in the amount of NOK 60 million. Apr 18
Circio Announces in Vivo Proof-Of-Concept for Its circVec circular RNA Platform Technology and Reinforced Gene Therapy Focus Apr 17
Forecast breakeven date pushed back to 2026 Apr 05
New minor risk - Financial data availability Mar 11
Circio Holding ASA Announces Dosing of First Patient in the Collaborative Phase 2 Trial Sponsored by Georgetown University Feb 01 Circio Holding ASA, Annual General Meeting, Jun 05, 2024
IOVaxis Therapeutics Files Updated TG01 Investigational New Drug Application with the Chinese National Medical Products Administration Dec 12
Circio Holding ASA Announces Completion of Planned Safety Review and Opening for Full Enrollment of TG01 Study At Oslo University Hospital Dec 07
New major risk - Financial position Oct 18 Aug 25
Forecast to breakeven in 2024 Apr 18
Forecast to breakeven in 2024 Mar 09
Targovax Announces That the TG01 Study in Multiple Myeloma At Oslo University Hospital Has Received Regulatory Approvals to Proceed Dec 23 Targovax ASA to Report Q4, 2023 Results on Feb 15, 2024
High number of new directors Nov 21
Targovax ASA Completes ONCOS-102 Phase 1b Study in PD-1 CPI Resistant Advanced Melanoma Has Been Published in the Oncology Journal Clinical Cancer Research Oct 21
Targovax ASA Receives Approval to Proceed with the Oncos-102 Phase 2 Melanoma Study from the US FDA Sep 28
Forecast to breakeven in 2024 Aug 22
Targovax ASA Announces that the FDA Grant Authorization to Initiate Clinical Trials with the Enhanced TG01 RAS Vaccine in the USA Jun 24
High number of new directors Apr 29
Targovax ASA Announces Board Changes Apr 21
Forecast to breakeven in 2024 Mar 12
Targovax ASA Appoints Lubor Gaal as Chief Financial Officer, Effective March 7, 2022 Feb 28
Forecast to breakeven in 2024 Feb 19
Targovax ASA Announces ONCOS-102 Achieves 25.0 Months Median Overall Survival in First Line Mesothelioma Dec 20
Chief Financial Officer Torbjørn Furuseth has left the company Oct 07
Targovax Receives Fast Track Designation for Oncos-102 in Melanoma Jun 23
Targovax Announces Completed Enrollment in the Phase 1/2 Trial with ONCOS-102 in Combination with Durvalumab in Patients with Advanced Colorectal Cancer with Peritoneal Malignancies Jun 17
Targovax ASA's ONCOS-102 Mesothelioma 24-Month Data Shows Class-Leading Median Overall Survival Jun 11
Targovax ASA Announces Board Changes Mar 18
Targovax Granted US Patent for Oncos-102 in Combination with Checkpoint Inhibitors Mar 09
Continued Survival Benefit in Targovax's ONCOS-102 Trial in Mesothelioma At the 21-Month Follow-Up Feb 24
Revenue misses expectations Feb 20
Targovax ASA Receives Fast-Track Designation for ONCOS-102 Feb 16 Targovax ASA and Papyrus Therapeutics Enter Research Collaboration to Develop Novel ONCOS Viruses with Receptor Tyrosine Kinase (RTK) Inhibitor Functionality
Targovax grants IOVaxis 3 months extension to the exclusive license option for TG mutant RAS vaccines in Greater China and Singapore Jan 06
New 90-day high: €1.02 Dec 29
New 90-day high: €0.86 Dec 04
Targovax ASA Demonstrates Encouraging Survival Data for Oncos-102 in Mesothelioma Nov 26
Revenue in line with expectations Nov 07 Targovax ASA to Report Q1, 2021 Final Results on May 06, 2021
Targovax Announces Formation of New Scientific Advisory Board Oct 29
New 90-day low: €0.57 Oct 22
Targovax ASA has completed a Follow-on Equity Offering in the amount of NOK 75.000003 million. Oct 16
Targovax ASA Announces ONCOS-102 and Durvalumab Trial Successfully Completes Part 1 in Colorectal Cancer Oct 13
New 90-day high: €0.72 Sep 24 Shareholder Returns TA50 DE Biotechs DE Market 7D -98.5% -1.2% -1.4% 1Y -99.9% -13.2% 8.0%
See full shareholder returns
Return vs Market: TA50 underperformed the German Market which returned 8% over the past year.
Price Volatility Is TA50's price volatile compared to industry and market? TA50 volatility TA50 Average Weekly Movement 5,457.5% Biotechs Industry Average Movement 6.7% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.9% 10% least volatile stocks in DE Market 2.5%
Stable Share Price: TA50's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: TA50's weekly volatility has increased from 3074% to 5438% over the past year.
About the Company Circio Holding ASA, a biotechnology company, develops novel circular RNA and immunotherapy medicines. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in human cells. It has a collaboration with Certest Biotec, S.L. for formulation of circVec into lipid nanoparticles.
Show more Circio Holding ASA Fundamentals Summary How do Circio Holding's earnings and revenue compare to its market cap? TA50 fundamental statistics Market cap €2.88m Earnings (TTM ) €806.52k Revenue (TTM ) €10.44k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) TA50 income statement (TTM ) Revenue NOK 123.00k Cost of Revenue NOK 0 Gross Profit NOK 123.00k Other Expenses -NOK 9.38m Earnings NOK 9.50m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) 0.21 Gross Margin 100.00% Net Profit Margin 7,722.76% Debt/Equity Ratio -81.1%
How did TA50 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/19 20:18 End of Day Share Price 2024/12/18 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Circio Holding ASA is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Arvid Necander Carnegie Investment Bank AB Geir Holom DNB Markets Jonas Peciulis Edison Investment Research
Show 2 more analysts 
